University of Louisville Hospital
Welcome,         Profile    Billing    Logout  
 109 Trials 
188 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kloecker, Goetz H
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).

Completed
3
298
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
11/24
11/24
NCT00682032: The Effect of Beta-glucan in Non-Small Cell Lung Cancer

Recruiting
N/A
300
US
beta-glucan, Imucell WGP
University of Louisville, James Graham Brown Cancer Center
Non Small Cell Lung Cancer
04/25
03/29
Wadhwa, Anupama
NCT05185791: ERAS® Guidelines Validation of CRS With or Without HIPEC

Recruiting
N/A
288
Europe, Canada, US
Pre-ERAS® phase (current clinical practice), Post-ERAS® implementation phase
Hospices Civils de Lyon
Peritoneal Diseases
06/22
08/22
Lenhardt, Rainer
NCT05486416: Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery

Completed
3
466
Europe, US
HSK3486, Propofol, Diprivan
Haisco-USA Pharmaceuticals, Inc.
General Anesthesia
07/24
07/24
NCT05156983 / 2021-004138-12: A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

Recruiting
3
328
Europe, Canada, US
TAK-330, SOC 4F-PCC
Takeda, Takeda Development Center Americas, Inc.
Coagulation Disorder
04/28
04/28
COMBO, NCT03080896: Video-Laryngoscope Alone or With Bronchoscope for Predicted Difficult Intubation

Completed
N/A
80
US
King Vision video-laryngoscope with #3 disposable blade and endotracheal tube stylet, Ambu aScope III, fiberoptic bronchoscope aScope III, aScope III by Ambu
University of Louisville, Ambu A/S
Intubation; Difficult
03/24
03/24
DA-TCI, NCT04866472: Comparison Using a VLS Using GlideRite Stylet Versus TCI Articulating Introducer in Predictive Difficult Intubation

Recruiting
N/A
160
US
video-laryngoscope and GlideRite Rigid Stylet, video-laryngoscope and TCI Articulating Introducer Device
University of Louisville, University of Utah
Predicted Difficult Airway
08/24
08/24
Martin, Robert
NCT06526338: Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone

Recruiting
2
126
US
1.0% IP-001 for injection, Surgical Resection and Local Ablation, Local Ablation Alone
Robert C. Martin
Hepatocellular Carcinoma
12/29
12/30
BCC-RAD-13, NCT02128100: Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer

Completed
2
5
US
Folfirinox, o Oxaliplatin, o Leucovorin, o Irinotecan, o Fluorouracil, Stereotactic Body Radiation Therapy
University of Louisville, James Graham Brown Cancer Center
Pancreatic Cancer Non-resectable
03/21
03/21
NCT03080974: Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Recruiting
2
10
US
Nivolumab, Irreversible Electroporation
University of Louisville
Pancreatic Adenocarcinoma
06/25
04/26
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recruiting
2
30
US
RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Replimune Inc., Roche Pharma AG
Hepatocellular Carcinoma
12/27
07/28
INJECTABL-1, NCT05688280 / 2022-000176-19: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Active, not recruiting
1/2
42
Europe, US
1.0% IP-001 for Injection, IP-001
Immunophotonics, Inc., Immunophotonics Inc.
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
02/25
02/25
NCT03484299: Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Recruiting
1
20
US
Irreversible Electroporation (IRE), Gemcitabine, FOLFIRINOX
University of Louisville
Pancreas Cancer
12/23
07/24
DIRECT, NCT03899649: A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer

Active, not recruiting
N/A
532
US
SOC, NanoKnife System
Angiodynamics, Inc.
Stage III Pancreatic Cancer
12/24
12/24
NCT02674100: American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

Recruiting
N/A
500
Europe, Canada, Japan, US, RoW
Registry
University of Louisville, The Americas Hepato-Pancreato-Biliary Association
Pancreatic Cancer
01/25
01/30
NCT05953337: Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

Recruiting
N/A
120
US
EYE90 Microspheres Treatment
ABK Biomedical
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer
10/25
10/25
CYBRID-02, NCT05520099: Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

Recruiting
N/A
216
US
Core Needle or Forceps Biopsy
Elephas, Hoosier Cancer Research Network
Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Cutaneous Melanoma, Endometrial Cancer, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
01/27
01/27
Dryden, Gerald W
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Completed
2
216
US, RoW
CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo
CalciMedica, Inc.
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
05/24
05/24
NCT05437029: Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray

Recruiting
1b
24
US
Q-Griffithsin 3.0, Q-Griffithsin Group 1, Q-Griffithsin 6.0, Q-Griffithsin Group 2
Kenneth Palmer, United States Department of Defense
COVID-19 Prevention
10/22
11/22
NCT01294072: Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue

Recruiting
N/A
35
US
curcumin, Curcumin conjugated with plant exosomes, No intervention
University of Louisville
Colon Cancer
11/24
11/24
MAAIS, NCT01169194: Multi-Center African-American Inflammatory Bowel Disease Study

Recruiting
N/A
2400
US
Johns Hopkins University, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Inflammatory Bowel Disease
08/27
08/27
HBOT-UC, NCT05987852: Hyperbaric Oxygen Therapy for Ulcerative Colitis

Recruiting
N/A
126
US
Hyperbaric Oxygen Therapy, Sham Hyperbaric Air
Northwestern University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Ulcerative Colitis
09/27
09/27
Clark, Laura
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

Active, not recruiting
2/3
186
NA
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo
Zydus Therapeutics Inc., Zydus Therapeutics Inc.
Primary Biliary Cholangitis
05/25
05/25
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis

Active, not recruiting
2
180
US, RoW
Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent
Zydus Therapeutics Inc.
Nonalcoholic Steatohepatitis, Fibrosis
07/25
07/25
VANTAGE, NCT05050136 / 2021-001389-39: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Recruiting
2
180
Europe, Canada, Japan, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Biliary Cholangitis, PBC
12/25
12/25
NCT02799485: sEphB4-HSA in Treating Patients With Kaposi Sarcoma

Active, not recruiting
2
23
US
Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Recombinant EphB4-HSA Fusion Protein, sEphB4-HSA
AIDS Malignancy Consortium, National Cancer Institute (NCI), Vasgene Therapeutics, Inc, The Emmes Company, LLC, University of Arkansas
Skin Kaposi Sarcoma
12/25
06/26
NCT04248192: Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)

Recruiting
1
8
US
DD HST-NEETs
Catherine Bollard
HIV-Infected Individuals
09/24
04/25
AMC-105, NCT04139304: A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Active, not recruiting
1
15
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine, LEUROCRISTINE, VCR, Vincrystine, Vincristine Sulfate, Kyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
AIDS Malignancy Consortium, National Cancer Institute (NCI), Janssen Scientific Affairs, LLC, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, AIDS and Cancer Specimen Resource, The Emmes Company, LLC
Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
07/25
08/27
NCT05510908: Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

Recruiting
N/A
720
US
Non-Interventional, Non-Interventional Follow-up
AIDS Malignancy Consortium, National Cancer Institute (NCI)
HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma, AIDS-related Kaposi Sarcoma, AIDS-Related Malignancy, Anal Cancer, HPV-Related Malignancy
11/25
09/26
NCT05663502: Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

Recruiting
N/A
200
US
Biospecimen Collection, Biological Sample Collection
AIDS Malignancy Consortium, National Cancer Institute (NCI)
Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Kaposi Sarcoma, Lymphoma, Malignant Solid Neoplasm, Multicentric Castleman Disease, Plasmablastic Lymphoma, Recurrent Kaposi Sarcoma, Recurrent Lymphoma, Recurrent Plasmablastic Lymphoma, Transplant-Related Kaposi Sarcoma
08/30
08/35
Liu, Wei
NCT06288334: Exploration of the Optimal Dosage of Cetirizine in the Treatment of Allergic Diseases in Chinese Children

Recruiting
4
80
RoW
1-3 Cetirizine Pharmacokinetic samples
Peking University Third Hospital
Allergic Disease, Children
03/24
05/24
NCT02864953 / 2017-004854-41: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

Terminated
3
535
Europe, Canada, Japan, US, RoW
BIIB093, glibenclamide, glibenclamide intravenous (IV), glyburide, CIRARA, Placebo
Remedy Pharmaceuticals, Inc.
Brain Edema, Stroke, Acute
08/23
08/23
MOST, NCT03735979: Multi-arm Optimization of Stroke Thrombolysis

Active, not recruiting
3
514
US
Argatroban, Eptifibatide, Placebo
Washington University School of Medicine, National Institute of Neurological Disorders and Stroke (NINDS)
Acute Ischemic Stroke
12/23
04/25
ASPIRE, NCT03907046: Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Recruiting
3
700
US
Apixaban, Eliquis, Aspirin
Yale University, National Institute of Neurological Disorders and Stroke (NINDS)
Intracerebral Hemorrhage, Atrial Fibrillation
04/27
04/27
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke

Recruiting
3
1380
RoW
Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin
Beijing Tiantan Hospital
Ischemic Stroke, Acute
12/25
12/26
ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Active, not recruiting
3
408
RoW
KN046, placebo
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Pancreatic Ductal Adenocarcinoma
04/24
08/24
NCT06434467: The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma

Not yet recruiting
3
83
RoW
Nelarabine injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma
12/25
05/26
NCT05545137: Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection

Completed
3
299
RoW
Pivmecillinam hydrochloride tablets, Selexid®, Fosfomycin Tromethamine Granules, Monurol®
Benova (Tianjin) Innovative medicine Research Co., Ltd.
Uncomplicated Urinary Tract Infection
02/24
02/24
NCT04438005: A Study of ICP-022 in Patients With R/R DLBCL

Completed
2
3
RoW
ICP-022
Beijing InnoCare Pharma Tech Co., Ltd.
Diffuse Large B Cell Lymphoma
11/21
12/21
NCT05346146: A Prospective, Single-arm, Exploratory Clinical Study of Sintilimab Injection in Combination With Paclitaxel (Albumin-bound) and Gemcitabine in Translational Therapy in Patients With Unresectable Locally Advanced Pancreatic Cancer.

Recruiting
2
20
RoW
Sintilimab; Gemcitabine; Albumin-paclitaxel
RenJi Hospital, Innovent Biologics (Suzhou) Co. Ltd.
Unresectable Locally Advanced Pancreatic Cancer
07/23
07/24
NCT03837873: DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Recruiting
2
118
RoW
Rituximab, Etoposide, Vincristine, Doxorubicin, Dexamethasone, Cyclophosphamide, Lenalidomide, Cisplatin, Cytarabine
Institute of Hematology & Blood Diseases Hospital
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma
09/23
09/24
NCT06244368: GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Recruiting
2
115
RoW
GVM±R regimen
Qiu Lugui
Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
06/25
06/27
MA-ASCT-II-002, NCT05294055: Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma

Recruiting
2
120
RoW
Etoposide, Cyclophosphamide, Mecapegfilgrastim, day 2, Mecapegfilgrastim, day 5
Qiu Lugui, Jiangsu Hengrui Pharmaceuticals Co.,Ltd
Multiple Myeloma, Lymphoma
03/24
09/24
NCT06489808: Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Recruiting
2
89
RoW
Linperlisib, Rituximab, Gemcitabine, Oxaliplatin, Ifosfamide, Carboplatin, Etoposide, Dexamethasone, Cisplatin, Ara-C, Vinorelbine, Mitoxantrone hydrochloride liposome
Institute of Hematology & Blood Diseases Hospital, China
Relapsed/Refractory Large B-Cell Lymphoma
12/26
05/27
NCT05997602: To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

Recruiting
2
56
RoW
FCN-159
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Langerhans Cell Histiocytosis, LCH
07/24
07/26
NCT04690192: CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

Active, not recruiting
1/2
20
RoW
CNCT19, Gemcitabine Injection, busulfan, Melphalan Injection
Zou Dehui, Juventas Cell Therapy Ltd.
Large B-cell Lymphoma
12/23
12/24
NCT06594640: R-CMOP in Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma

Recruiting
1/2
108
RoW
Mitoxantrone Hydrochloride Liposome, Rituximab (R), Cyclophosphamide (CTX), Vincristin, Prednisolone
Qiu Lugui
Diffuse Large B-cell Lymphoma
06/26
07/27
NCT04464551: The Absorption, Metabolism and Excretion of [14C]D-0316 in Human

Active, not recruiting
1
4
RoW
[14C]D-0316 suspension
Betta Pharmaceuticals Co., Ltd.
Advanced or Metastatic Non-small Cell Lung
08/21
08/21
NCT04696705: Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients

Recruiting
1
10
RoW
Ex-vivo expanded allogeneic γδT cells
Institute of Hematology & Blood Diseases Hospital, Beijing GD Initiative Cell Therapy Technology Co., Ltd., Chinese Academy of Medical Sciences
Non-Hodgkin's Lymphoma (NHL), Peripheral T Cell Lymphoma (PTCL)
12/21
12/23
CSPC-DED-DLBCL-K02, NCT05299164: GVM±R in Patients With Relapsed or Refractory Aggressive NHL

Active, not recruiting
1
18
RoW
Liposomal Mitoxantrone Hydrochloride dose level 1, Liposomal Mitoxantrone Hydrochloride dose level 2, Liposomal Mitoxantrone Hydrochloride dose level 3, Liposomal Mitoxantrone Hydrochloride dose level 4
Institute of Hematology & Blood Diseases Hospital, China, CSPC Ouyi Pharmaceutical Co., Ltd.
Non Hodgkin Lymphoma
12/23
12/25
NCT05318963: Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

Recruiting
1
34
RoW
LCAR-AIO cells product
Qiu Lugui, Nanjing Legend Biotech Co.
B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
06/24
06/26
UDACPPNAC, NCT05043194: Ursodeoxycholic Acid Prevents Total Parenteral Nutrition Cholestasis

Recruiting
N/A
80
RoW
Ursodeoxycholic Acid 250 Mg Oral Capsule
Wei Liu
Cholestasis of Parenteral Nutrition
09/21
07/22
NCT04307030: Study on AI Recognition System Of Heart Sound In Congenital Heart Disease Screening

Recruiting
N/A
5000
RoW
Heart Auscultation and Echocardiography
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Congenital Heart Disease in Children
12/21
06/23
PLAND, NCT03498885: Comparison of Low and High Ligation With Apical Lymph Node Dissection in the Laparoscopy Rectal Cancer

Recruiting
N/A
466
RoW
Low ligation, LL, High ligation, HL
WEIDONG LIU，MD
Rectal Cancer
12/22
12/25
NCT04853238: Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China

Completed
N/A
1507
RoW
Prospective observational cohort study
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
11/22
02/23
NCT03621631: Effect of Tai Chi Exercise on Mechanical Joint Loading in Knee Osteoarthritis

Recruiting
N/A
60
US
Optimized Tai Chi intervention, OTC, Traditional Tai Chi intervention, TTC
Edward Via Virginia College of Osteopathic Medicine, National Center for Complementary and Integrative Health (NCCIH), The University of Texas Health Science Center at San Antonio
Knee Osteoarthritis
07/23
09/23
NCT02515474: Comparison of LCBDE vs ERCP + LC for Choledocholithiasis

Completed
N/A
1000
RoW
Laparoscopy, Laparoscopic common bile duct exploration (LCBDE), Endoscopy, Endoscopic Retrograde cholangiopancreatography (ERCP)
Hepatopancreatobiliary Surgery Institute of Gansu Province
Choledocholithiasis
01/24
01/24
NCT06249087: Multifunctional Nutrition Tube on Social Condition and Experience in Cerebralvascular Accident

Recruiting
N/A
80
RoW
comprehensive rehabilitation therapy, Intermittent Oro-esophageal Tube Feeding, Nasogastric Tube Feeding
Zeng Changhao
Stroke
05/24
05/24
NCT06255730: The Effect of Stellate Ganglion Block on Insomnia Patients

Recruiting
N/A
50
RoW
Stellate Ganglion Block, Lidocaine Hydrochloride
Zeng Changhao
Insomnia
06/24
06/24
NAOTAN-IOE, NCT06269835: Intermittent Multifunctional Nutrition Tube in Cerebral Palsy and Dysphagia

Recruiting
N/A
100
RoW
systemic therapy, Intermittent Oro-Esophageal Tube Feeding, Persistent Nasogastric Tube Feeding
Zeng Changhao
Cerebral Palsy
12/24
12/24
NCT06255353: Effect of Different Feeding Modes in Intracerebral Hemorrhage

Recruiting
N/A
120
RoW
Intermittent Oro-esophageal Tube Feeding, Basic treatment, Nasogastric Tube Feeding
Zeng Changhao
Intracerebral Hemorrhage
06/24
06/24
IOE+JLCJ-S, NCT06265779: Transcranial Direct Current Stimulation Combined With Intermittent Oral to Esophageal Tube on Dysphagia

Recruiting
N/A
84
RoW
Comprehensive rehabilitation therapy, Intermittent Oro-esophageal Tube Feeding, Transcranial direct current stimulation
Zeng Changhao, The First Affiliated Hospital of Zhengzhou University
Cerebral Infarction
11/24
12/24
ABE-S, NCT06265818: The Effect of Active Breathing Exercises in Stroke Patients With Respiratory Rhythm Disorder

Recruiting
N/A
80
RoW
Rehabilitation training, Active Breathing Exercises
Zeng Changhao, The First Affiliated Hospital of Zhengzhou University
Respiratory Rhythm Disorder
05/24
05/24
PlaqueVision, NCT06681155: Identification Of High-risk Coronary Plaques By Multimodal Intravascular Imaging

Not yet recruiting
N/A
500
RoW
Assessment of plaque morphology, structure, and stability in non-culprit lesions
Chinese PLA General Hospital
Coronary Arterial Disease (CAD), Acute Coronary Syndromes
12/27
12/31
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus

Recruiting
N/A
184
RoW
Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter
Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Coronary Artery Disease, Intravascular Lithotripsy
12/24
09/25
NCT05449106: Evaluation of Clinical Outcomes of Unruptured bAVMs Treated With Medical Management Alone Based on Multimodal CT

Recruiting
N/A
200
RoW
Beijing Tiantan Hospital, Beijing Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital of Zhengzhou University
Brain Arteriovenous Malformations
05/27
05/32
NCT04805853: Myocardial Pathological Changes in Patients of Type 2 Diabetes With or Without PCOS Using Cardiac Magnetic Resonance

Recruiting
N/A
561
RoW
RenJi Hospital
Type2 Diabetes, Polycystic Ovary Syndrome
02/22
02/22
NCT05463627: Effects of Metformin on Metabolic and Reproductive Outcomes in Chinese PCOS Patients

Recruiting
N/A
1440
RoW
Metformin, melbine
RenJi Hospital
Polycystic Ovary Syndrome, Metformin
01/23
01/23
NCT04830826: A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

Recruiting
N/A
2000
RoW
Surgeries
The First Affiliated Hospital of Guangzhou Medical University
NSCLC, Stage I, NSCLC, Stage II, NSCLC, Stage III
01/24
07/24
Redman, Rebecca
NCT03811015: Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Suspended
3
636
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
01/27
01/27
NRG-HN009, NCT05050162: Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Recruiting
2/3
464
Europe, Canada, US, RoW
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
NRG Oncology, National Cancer Institute (NCI)
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary
02/31
02/36
NCT05366166: Pembrolizumab Plus Olaparib in LA-HNSCC

Recruiting
2
45
US
Pembrolizumab, KEYTRUDA®, MK-3475, Olaparib, AZD-2281, MK-7339, KU0059436, Cisplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-platinum, IMRT (intensity modulated radiation therapy)
UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of Head and Neck
10/25
10/26
BCC-RAD-13, NCT02128100: Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer

Completed
2
5
US
Folfirinox, o Oxaliplatin, o Leucovorin, o Irinotecan, o Fluorouracil, Stereotactic Body Radiation Therapy
University of Louisville, James Graham Brown Cancer Center
Pancreatic Cancer Non-resectable
03/21
03/21
NCT02734537: Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Recruiting
2
189
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
12/27
12/27
KEYNOTE-877, NCT03674567: Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

Active, not recruiting
1/2
323
US, RoW
FLX475, pembrolizumab (KEYTRUDA®)
RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC
Advanced Cancer
09/24
01/25
KEYNOTE F92, NCT05597839: Study of DF9001 in Patients With Advanced Solid Tumors

Recruiting
1/2
242
US
DF9001, pembrolizumab, KEYTRUDA®
Dragonfly Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult
08/25
11/27
NCT02922764: A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Checkmark From a trial for solid tumors
Jun 2020 - Jun 2020: From a trial for solid tumors
Active, not recruiting
1
146
US
RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed
Inspirna, Inc.
Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
12/24
12/24
MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated
1
64
US
MT-6402
Molecular Templates, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
10/24
10/24
NRG-HN008, NCT04533750: Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Active, not recruiting
1
42
US
Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Peposertib, 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-, M 3814, M-3814, M3814, MSC 2490484A, MSC-2490484A, MSC2490484A, Nedisertib, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI), NRG Oncology
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oral Cavity Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
07/25
07/25
SRF114-101, NCT05635643: Study of CHS-114 in Participants With Advanced Solid Tumors

Hourglass Jan 2024 - Jun 2024 : Results from SRF114-101 trial for advanced solid tumors
Recruiting
1
47
US
CHS-114, toripaliamab, Loqtorzi
Coherus Biosciences, Inc.
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
02/26
02/26
McClain, Craig J
SACRED, NCT03654053: Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis

Active, not recruiting
3
142
US
Placebo Oral Tablet, Placebo, Simvastatin 40mg, Simvastatin
VA Office of Research and Development
Cirrhosis
12/25
12/25
DUR-928/AH, NCT03917407: DUR-928 in Patients With Alcoholic Hepatitis

Completed
2
43
US
DUR-928 (Moderate AH), Sulfated oxysterol: 5 cholesten-3β, 25-diol 3-sulfate (25HC3S), DUR-928 (Severe AH)
Craig James McClain, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcoholic Hepatitis
09/23
09/23
AUD+ALD, NCT05178069: LGG Supplementation in Patients With AUD and ALD

Recruiting
2
60
US
: Placebo for Probiotic, Dummy capsule, Lactobacillus Rhamnosus GG, Culturelle
University of Louisville, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder, Alcohol-associated Liver Disease
08/26
02/27
NCT04174001: Perioperative Cerebrovascular Autoregulation Monitoring in Neurosurgical Patients

Recruiting
N/A
30
US
Boston Children's Hospital
Cerebral Hemodynamics
12/24
12/24
NCT03850899: Alcoholic Hepatitis Network Observational Study

Completed
N/A
1134
US
Indiana University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcoholic Hepatitis
06/24
06/24
Contact, Central
NCT03641560: A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Completed
4
52
RoW
Enzalutamide, MDV3100, Xtandi, Androgen deprivation therapy (ADT)
Astellas Pharma Inc
Metastatic Castration Resistant Prostate Cancer
02/24
02/24
NCT03684018 / 2018-003430-33: Two Dose Levels of Privigen in Pediatric CIDP

Recruiting
4
30
US
IgPro10, Privigen
CSL Behring
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12/29
12/29
NCT02294461: An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Completed
3
395
RoW
Enzalutamide, Xtandi, MDV3100, Placebo
Astellas Pharma Inc
Progressive Metastatic Prostate Cancer
09/15
07/24
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Recruiting
3
177
Canada, US
IgPro20, HIZENTRA®, Placebo
CSL Behring
Post-COVID Postural Orthostatic Tachycardia Syndrome
09/27
09/27
NCT06617897: Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

Recruiting
3
90
Europe
CSL511 Fibrinogen concentrate (human), Cryoprecipitate
CSL Behring
Acquired Fibrinogen Deficiency
09/26
10/26
TAP, NCT05568888: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( Study )

Terminated
3
1370
Europe, US, RoW
BE1116, 4-Factor Prothrombin Complex, Kcentra®, Beriplex®, Placebo
CSL Behring
Traumatic Injury
10/24
10/24
NCT02439268: The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf®) in Advanced Patients Harboring the V600 BRAF Mutation

Active, not recruiting
2
100
RoW
Vemurafenib, Zelboraf, Vemurafenib (CT), RO5185426, PLX4032
Cancer Centre of Monoclonal Therapy, LLC, The European Association for Cancer Research, Melanoma Research Foundation, Alliance for Clinical Trials in Oncology in EU
Colorectal Cancer, Recurrent/Refractory BRAFV600E-mutant Gliomas, Advanced Cancers, Melanoma, Advanced BRAF-mutant Cancers
07/15
05/18
 

Download Options